Sutetinib
Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo[1].
Product Specifications
CAS Number
1259519-20-4
UNSPSC
12352005
Target
EGFR; PDGFR; VEGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sutetinib.html
Purity
99.27
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCOC(C(NC(/C=C/CN(C)C)=O)=C1)=CC2=C1C(NC3=CC(C#C)=CC=C3)=C(C#N)C=N2
Molecular Formula
C26H25N5O2
Molecular Weight
439.51
References & Citations
[1]Hao Z, et al., Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016 Sep 8;9:5495-505.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TGF-beta (1D11.16.8), CF640R conjugate, 0.1mg/mL
Human IgG Immunoglobulin (IG266), CF488A conjugate, 0.1mg/mL
Eosinophil Peroxidase (AHE-1), CF640R conjugate, 0.1mg/mL
